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Abstract
Background:  Atypical glandular cells on cervical smears are often associated with clinically
significant uterine lesions. The frequency and accuracy of AGC-NOS (i.e. atypical glandular cells,
not otherwise specified) diagnoses, regardless of the gland cell type or the degree of suspicion, and
their outcome were investigated.
Methods: From January 1, 1990 to December 31, 1999 a total of 261 patients had an AGC-NOS
diagnosis made by conventional cervical Papanicolaou smear interpretation representing 0.05% of
all Pap-smears analyzed at the national level. 191 (73.2%) patients had a subsequent histological
examination, 8 samples were not representative by origin and were excluded.
Results: Out of 183 AGC-NOS diagnosed, 56.3% (103/183) were associated with tissue-proven
precancerous and/or cancerous lesions, 44% being of endocervical and 56% of endometrial origin.
75% of all AGC-patients were asymptomatic. 66.7% (6/9) of the patients with subsequent invasive
endocervical adenocarcinoma (AC) and 56% (28/50) of those patients with invasive endometrial
AC were without clinical symptoms. 3 patients out of 9 with an invasive endocervical AC were 35
years of age or less. 10.1% and 12.3% of all 'new' tissue-proven invasive endocervical or endometrial
AC respectively recorded by the national Morphologic Tumour Registry (MTR) were first
identified by a cytological AGC-NOS diagnosis.
Conclusion: Our findings emphasize the importance of the cytological AGC-category even in the
absence of a precise origin or cell type specification. 56% of the AGC-diagnoses being associated
with significant cancerous or precancerous conditions, a complete and careful evaluation is
required.
Background
According to the 'original' definitions of "The Bethesda-
System" (TBS, 1989, 2001) for reporting cervico-vaginal
cytological diagnoses and in analogy to the Munich II-
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classification modified by Soost in 1989 (Table 1) the cur-
rent study focuses on the 'former' atypical glandular cells
of undetermined significance (AGUS/TBS versus Class III
G/MUNICH II) diagnosed during the 1990's in a non-aca-
demic laboratory [1-7]. It has been generally accepted that
the cervical cyto-histological correlation can be consid-
ered as one method, predominantly used by cytology lab-
oratories to conduct quality assurance [6,7]. The AGUS,
now AGC-NOS (i.e. atypical glandular cells, not otherwise
specified) category and its counterpart ASCUS (atypical
squamous cells of undetermined significance) were often
excluded from cyto-histological correlations [8,9]. As a
follow-up study of AGC-diagnoses, we reviewed our
results in order to determine the frequency of the AGC
diagnoses in general and the age distribution of the
patients. Beside we examined time trends and their corre-
lation with the corresponding available histopathological
results.
Methods
From January 1, 1990 to December 31, 1999, a total of
566.809 cervico-vaginal smears were screened at the cen-
tral division of clinical cytology of the National Health
Laboratory (NHL) in Luxembourg (Western Europe). All
smears were conventional smears and no liquid based
preparation was used. 261 cases were categorized as AGUS
versus Cl III G diagnoses and correlated with the his-
topathological diagnoses collected by the National Mor-
phologic Tumour Registry (MTR).
The AGUS category was defined by the TBS (1989) as
atypical glandular cells of undetermined significance
showing either endocervical or endometrial differentia-
tion, with nuclear atypia that exceeds obvious reactive or
reparative changes including endocervical in situ adeno-
carcinomas but lacking unequivocal features of invasive
adenocarcinomas [1]. By analogy, the Munich II-classifi-
cation modified by Soost (Table 1), used in our labora-
tory, defines the Cl III G as abnormal cells of the glandular
epithelium, whose carcinomatous nature cannot be
excluded with certainty, and recommends, if possible, a
statement concerning the endometrial, endocervical or
extra-uterine origin of the cells [5]. During the observa-
tion period 1990 to 1999 the AGUS/Cl III G – diagnoses
in our series were not qualified, neither by site, nor by cri-
teria favoring reactive or neoplastic aspects. Patients with
benign endocervical or endometrial cell changes and
patients with unequivocally malignant glandular cells
described by the TBS were not considered. In this study,
we have used the term 'AGC-NOS' for 'atypical glandular
cells, not otherwise specified' of the new Bethesda 2001
nomenclature instead of AGUS.
To guarantee the technical quality of the smears, all the
material needed to take samples, transport and prepare
the smears (wooden "Ayre" spatula, cotton swab, flask for
transport, ether-alcohol fixative, slides) were provided to
the general practitioners and gynecologists collaborating
as 'smear takers' [10]. The smears were then analyzed by
cytotechnologists with a maximal work load of 76 Harris-
Table 1: Classification of Munich (II), modified by Soost in 1989 [5].
Class Cytological description Recommendation
I Normal cells /
II Regenerative cells, immature metaplastic cells, important 
degenerative or inflammatory changes, para- and hyperkeratinizing 
cells. Normal endometrial cells even after the menopause.
cytological control if necessary (with or without anti-inflammatory 
or hormonal treatment)
III Important degenerative, iatrogenic or inflammatory changes of the 
cells where benignity or malignancy cannot be diagnosed with 
certainty even if the smear is adequately prepared.
short-term cytological control if necessary after anti-inflammatory 
or hormonal treatment, or immediate histological control
IIID Mild to moderate dysplasia (CIN I and II) cytological control in 3 months
IIIG Abnormal cells of the glandular epithelium whose carcinomatous 
nature cannot be excluded with certainty; if possible with an 
indication of the endometrial, endocervical or extra-uterine origin 
of the cells.
cytological or histological control
IV a Severe dysplasia or carcinoma in situ (CIN III) histological control
IV b Severe dysplasia or carcinoma in situ; invasive carcinoma not 
excluded
histological control
V Invasive epidermoid carcinoma of the uterine cervix; 
adenocarcinoma, indicating if possible the endometrial, 
endocervical or extra-uterine origin of the cells. Other malignant 
tumours.
histological controlBMC Cancer 2004, 4:37 http://www.biomedcentral.com/1471-2407/4/37
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Shorr stained slides per day, and 8 slides chosen at ran-
dom for double-check [11]. All AGC-NOS cases were
examined by the chief cytotechnologist as well as the
cytopathologist responsible for the original cytological
diagnosis. To ensure diagnostic quality, the cytopatholo-
gist had access to all case histories with a high rate of his-
tologic correlates and which are centralized at the national
histopathology division of the NHL.
The cyto-histological correlation being a common com-
ponent of quality assurance and improvement programs
in cytopathology laboratories, we analysed our AGC-NOS
cases to provide a reference database for intra- and inter-
laboratory comparison of performance [6,12,13]. The
quality assurance monitors were the cyto-histological cor-
relations and the AGC-NOS/in situ AC versus the AGC-
NOS/invasive AC ratio, including the comparison with
the AC diagnosed in a well-defined area (i.e. patients of all
nationalities living in the Grand-Duchy of Luxembourg).
All the cancer cases were registered during the study
period (1990–1999) by the national cancer registry,
which records all in situ and invasive cancers of all sites
diagnosed by morphological methods (i.e. histology and
cytology) in Luxembourg [8,14,15]. With the access to all
reports of the central department of pathology, the files of
the national MTR and the 'governmental' administrative
population data of all inhabitants, only 24 of the 261
patients were lost for follow-up. 16 patients quit the coun-
try and 8 patients died within 3 months after the cytolog-
ical diagnosis. The causes of death were not related to
uterine disease.
Patients were stratified into three different classes: those
having histopathological examinations with precise diag-
noses, those with repeat cytological screening only, and
those without follow-up data. The follow-up observation
period after the last AGC-NOS diagnosis in December 31,
1999 was at least 24 months. The cyto-histological corre-
lations were recorded for patients with a subsequent his-
tological tissue examination (i.e. cervical micro-biopsy,
conization, endocervical and/or endometrial curettage
and hysterectomy specimens). The results of the most rep-
resentative of these procedures and with the most serious
histological diagnosis were retained. For the purpose of
the present study we reviewed the cytological (CW) and
the histological (RS) slides of all AGC-cases.
The number of in situ or invasive, endocervical and
endometrial adenocarcinomas initially detected by cer-
vico-vaginal smears with an AGC-NOS diagnosis were
compared with all 'new' tissue-proven in situ or invasive,
endocervical or endometrial adenocarcinomas diagnosed
in the Grand-Duchy of Luxembourg during the review
period and registered by the MTR [14,15]. Out of 495
patients with an invasive uterine AC only 30 patients had
a preceding Pap-smear with an unequivocal malignant
cytological diagnosis. Duplicate registrations were
excluded. The tumour stages were classified by the TNM
system of the 'Union Internationale Contre le Cancer'/
UICC, 1997 [16].
The chi-square-test (χ2) with the Yates correction was used
to determine the statistical significance of the differences
in the time trends of the AGC-diagnoses over the study
period from 1990 to 1999. The level of significance was
<0.05.
Results
566.809 conventional cervico-vaginal Pap-smears were
examined during the 10-years observation period (Table
2) [17]. An AGC diagnosis 'not otherwise specified' was
made in 261 cases corresponding to 0.05% of all cervical
Pap-smears. 24 patients (9.2%) were lost to follow-up and
46 patients (17.6%) had repeat cytology only. 70 AGC
patients (26.8%) had no histological follow-up data.
From 191 patients (73.2%) who had a subsequent histo-
logical examination only 8 samples were not representa-
tive by site (i.e. exocervical biopsies) and had to be
excluded. 71 patients had hysterectomy preceded by a
curettage of the cervix and the corpus.
In Fig. 1, the age distribution is represented. 5.4% of the
261 patients with an AGC-NOS diagnosis were 35 years of
age or less, whereas 94.6% were aged 36 years and above.
The mean age of the patients was 54.9 years (range 18 to
93 years).
63 (24.1%) of the 261 women with an AGC-NOS diagno-
sis had clinical symptoms (i.e. abnormal vaginal bleed-
ing), whereas 198 (75.9%) patients were asymptomatic
(Table 3). The 'symptomatic/asymptomatic-ratio' catego-
rised by age groups was 1:13 for women 35 years old or
less (n = 14) and 1:2. 9 (62/185) for women aged 36 years
and above. In our series only 1 of the 4 patients with a tis-
sue-proven endocervical adenocarcinoma in situ (AIS)
and 3 of the 9 patients with an invasive endocervical AC
were symptomatic. 28 of the 50 patients (56%) with a tis-
sue-proven invasive endometrial adenocarcinoma had no
clinical symptoms.
Table 4 shows the cyto-histological correlations of 183
AGC-NOS cases. Out of 60 patients (32.8%) with a tissue-
proven endocervical lesion 28 patients had an intraepithe-
lial squamous cell lesion with endocervical glandular
involvement and 3 patients an invasive endocervical
squamous cell carcinoma. 120 patients (65.6%) had an
endometrial lesion. 3 patients had a metastatic adenocarci-
noma to the vagina (1.6%), 1 being of rectal origin, 1 of
ovarian and 1 of endometrial origin. 56.3% of all histo-
logically verified AGC-NOS diagnoses were associatedBMC Cancer 2004, 4:37 http://www.biomedcentral.com/1471-2407/4/37
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with a precancerous and/or cancerous lesion. Excluding
the 3 metastatic AC, we found 44% (44/100) of the pre-
cancerous or cancerous lesions with an endocervical origin
and 56% (56/100) with an endometrial origin.
From nine invasive endocervical  adenocarcinomas one
case (pT1a1) was removed by conization and six cases
(pT1b) were treated by hysterectomy. 2 cases diagnosed
by biopsy were lost for follow-up. The mean age of these
patients was 47 years (range:34–61) 2 patients were 34
and one 35. One of the 34-year-old patients had abnor-
mal vaginal bleeding.
Out of the 50 patients with a biopsy-proven endometrial
adenocarcinoma, 47 patients had an histological confir-
mation by curettage and were treated by hysterectomy. 38
(80.9%) of these had an 'early stage' adenocarcinoma of
the endometrium limited to the corpus (pT1a:n = 7;
pT1b:n = 16; pT1c:n = 15). 7 patients suffered from an AC
invading the cervix without extending beyond the uterus
(pT2a:n = 4; pT2b:n = 3). 2 women had advanced
tumours with an involvement of the serosa (pT3a:n = 2).
The mean age of these patients was 64.7 (range: 47–84).
22 patients (22/50; 44%) reported abnormal vaginal
bleeding, but 28 women (28/50; 56%) especially those
with early stage endometrial AC had no symptoms sugges-
tive of a significant uterine lesion.
We compared our 59 cases of invasive uterine adenocarci-
nomas identified by a cytological AGC-NOS diagnosis to
all  tissue-proven uterine adenocarcinomas recorded by
the national cancer registry during the observation period.
10.1% (9/89; 95% c.i., 0.04–0.16) of the invasive
endocervical adenocarcinomas and 12.3% (50/406; 95%
c.i., 0.09–0.16) of the invasive endometrial adenocarcino-
mas were first suggested by an AGC-diagnosis and subse-
quently confirmed by a histological examination.
In Table 5, our findings are compared to those of some
other studies published in the 1990's [8,18-23].
Discussion
Although the study period ended before 'Bethesda 2001'
it has to be emphasized that the term AGUS has been
eliminated to avoid confusion with ASC-US and changed
in AGC-NOS for atypical glandular cells not otherwise
specified [7].
According to the 'original' Bethesda system (1989) or the
Munich II-classification modified by Soost (1989), we
defined atypical glandular cells of undetermined signifi-
cance as cells that were not specified by site, and
displaying nuclear atypia that exceeded obvious reactive
or reparative changes but lacked unequivocal features of
invasive adenocarcinoma [1,3]. This means that an aden-
ocarcinoma cannot be excluded with certainty. We omit a
more detailed qualification, as the low reproducibility of
this cytological category was generally accepted, especially
in view of a precise origin [8,20,23-25]. Unfortunately,
despite this restrictive interpretation attitude, we had to
accept that 8 patients only had an exocervical 'not
representative' histological examination (Table 4). Today
our classification system would correspond to the AGC-
NOS (i.e. atypical glandular cells not otherwise specified)
as recommended by TBS 2001.
AGC-NOS is known as an uncommon cytological diagno-
sis and should represent for less than 1% of a laboratory's
workload [7,26]. In the current study (Table 2) we found
261 'new' AGC-NOS cases diagnosed by cervico-vaginal
Table 2: Demographic data, follow-up and diagnostic procedures (period 1990–1999)
1990–1994 1995–1999 P-Value TOTAL
Population * >15 years: at risk 833,964 884,947
Number of smears (cases) 241,098 325,711 p < 0,05 566,809
AGC-NOS/Cl.IIIG**-cases rate per 5 years period 46 0.02% 215 0.07% p < 0,001 261 (100%) 0.05%
Follow-up (F.u.):*** patients with
no histology (no F.u. or cytology only) 8 62 p < 0,05 70 (26.8%)
Available histologic findings ****: 38 (82.6%) 153 (71.2%) p < 0,05 191 (73.2%)
Diagnostic procedures: 191 (100%)
º cervical biopsies 4 16 p < 0,05 20 (10.4%)
º conization 4 17 p < 0,05 21 (11.0%)
º curettage 14 65 p < 0,05 79 (41.4%)
º hysterectomy 16 55 p < 0,05 71 (37.2%)
*Statec [17]; ** Division of clinical Cytology (NHL); *** 24 months; **** Division of anatomic pathology (NHL)BMC Cancer 2004, 4:37 http://www.biomedcentral.com/1471-2407/4/37
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Age distribution of AGC-NOS diagnoses (n = 261 cases) versus tissue-proven in situ and invasive endocervical (n = 13 cases)  and endometrial (n = 53 cases) adenocarcinomas (AC); endocervical squamous intraepithelial lesions (SIL; n = 28 cases) and  invasive squamous carcinomas (ISC; n = 3 cases) Figure 1
Age distribution of AGC-NOS diagnoses (n = 261 cases) versus tissue-proven in situ and invasive endocervical (n = 13 cases) 
and endometrial (n = 53 cases) adenocarcinomas (AC); endocervical squamous intraepithelial lesions (SIL; n = 28 cases) and 
invasive squamous carcinomas (ISC; n = 3 cases)
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cytology in our population, representing an AGC rate of
0.05% and increasing from 0.01% in 1990 to 0.09% in
1999. Other laboratories reported AGC rates ranging from
0.09% to 2.5% [8,18,20-22,27-29]. The reason why the
prevalence of AGC in our series is considerably lower than
that reported in other studies may be due to the exclusion
of 25 cases with atypical 'epithelial' cells at the beginning
of the 1990's. At revision, these cases had a glandular his-
topathological correlate (i.e. nine endocervical polyps,
fourteen endometrial polyps, one glandular-cystic hyper-
plasia and one endometrial AC). During the observation
period (1990–1999), there was a significant continuous
increase (p < 0.001) in cytological AGC-NOS diagnoses.
This was probably due to a more intensive education and
training of the cytologists in our institution and a more
defensive cytological practice in relation with a lack of
reliable cytological criteria [26]. In our series the AGC-
NOS category was not systematically used instead of une-
quivocal malignant glandular cells diagnoses (n = 30
cases) which were reported separately. Unfortunately we
found an increasing reluctance of the cytologists to give an
unequivocal prediction of glandular neoplasia. As the
Table 3: AGC-NOS patients with and without symptoms (i.e. abnormal vaginal bleeding) stratified by age groups. (n = 261 cases).
Age at diagnosis no symptoms (%) abnormal vaginal bleeding (%)
≤34 years 13 (5.0) 1 (0.4)
35–44 years 32 (12.3) 3 (1.1)
45–54 years 51 (19.6) 14 (5.4)
55–59 years 33 (12.6) 9 (3.4)
60–69 years 36 (13.8) 18 (6.9)
70–79 years 21 (8.0) 13 (5.0)
>80 years 12 (4.6) 5 (1.9)
TOTAL: n = 261 (100%) 198 (75.9%) 63 (24.1%)
Table 4: AGC-NOS and cyto-histological correlations (1990–1999)
90–94 95–99 TOTAL
HISTOLOGICAL DIAGNOSES* 38 153 191
not representative samples 178
ENDOCERVICAL LESIONS:
intrauterine device 11
microglandular adenoses 22
endocervical polyps 21 1 1 3
SIL**:
mild dysplasia 33
moderate dysplasia 246
severe dysplasia 167
squamous in situ carc.*** 39 1 2
squamous invasive carc. 123
adenocarcinoma in situ 224
adenocarcinoma invasive 279
ENDOMETRIAL LESIONS:
WNL**** 31 9 2 2
Arias-Stella changes 123
glandulo-cystic hyperplasia 55
submucosal leiomyoma 358
endometrial polyps 62 0 2 6
atypical endometrial hyperplasia 123
adenocarcinoma in situ 123
adenocarcinoma invasive 94 1 5 0
metastatic adenocarcinomas of rectal, ovarian, endometrial origin to the vagina 33
* histology: biopsy, cone, curettage, hysterectomy ** SIL: squamous intraepithelial lesion with endocervical glandular involvement *** carc.: 
carcinoma **** WNL:within normal limitsBMC Cancer 2004, 4:37 http://www.biomedcentral.com/1471-2407/4/37
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number of unequivocal malignant glandular cell
diagnoses decreased from 21 cases in the period 1990–
1994 to 9 cases in the period 1995–1999, a concomitant
decrease in the issue of reports giving a precise prediction
of glandular neoplasia must be admitted too. This may
inflate the follow-up rate of cancer associated with AGC-
NOS as well. At the rescreening for the purposes of the
present study 13 cases (5%) of the 261 smears with an
AGC-diagnosis had to be reclassified as malignant cyto-
logical diagnoses. On the other hand the increase in inva-
sive adenocarcinomas of both cervix and particularly
endometrium associated with AGC-NOS cytological pre-
diction may also be attributed to changes in clinical and
in cytological practices. In 1992, an organized national
breast cancer screening program started targeting women
between 50 and 64 years and reaching a participation rate
of more than 50%. It seems that the close multidiscipli-
nary collaboration (gynecologists, radiologists,
cytopathologists) initiated by this program has had a sec-
ondary sensitizing effect on the concerned health care
professionals and the invited women as well. So it seems
that older women were targeted for PAP-smears more fre-
quently after 1992. Perhaps this has affected partially the
predominance of endometrial lesions following AGC. The
fact that all our clinicians used a cotton swab to obtain the
endocervical sample may be disturbing. It has been dem-
onstrated by some authors that this is an inferior tech-
nique for obtaining a sample from the cervical canal and
emphasis is placed on the cytobrush in many countries.
The high percentage of early stage endometrial adenocar-
cinomas without symptoms and our finding that primary
diagnosis of malignancy was made by cytology in a signif-
icant number of cases in our population do not support
the opinion that the use of cotton swab is an obsolete
technique. The file review in our laboratory suggests, that
there is no significantly increased likelihood that cytology
was taken in women clinically suspected having endome-
trial neoplasia. Indeed, 33% of the patients with an
endocervical AC and 56% with an endometrial AC were
asymptomatic (Table 3). These observations are in con-
trast to the findings of Hare et al. [29] who describe 28.3%
asymptomatic patients with invasive endocervical AC
diagnosed with the cytobrush technique. All of there 15
endometrial AC were symptomatic. Jackson et al. [30]
reported a series of 34 asymptomatic cases giving a final
outcome of cervical glandular neoplasia in 45% including
just one case of invasive disease.
It is generally accepted that the cytological distinction
between reactive, inflammatory, irritative and dysplastic
or neoplastic alterated squamous and/or glandular prolif-
erations is complex and may be controversial for the
cytopathologists and the surgical pathologists alike
[31,32]. In a study of Raab SS and co-workers [23] an
interobserver variability of Papanicolaou smear diagnoses
of atypical glandular cells of undetermined significance
with a sensitivity of only 63% and a specificity of 58% is
reported. Our tissue-proven follow-up findings are sum-
marized in Table 4, and regroup the spectrum of potential
pitfalls, that had also been reported by other groups
[30,33-38]. So 31 of our AGC-cases were associated with
tissue-proven endocervical squamous lesions, 28 corre-
sponding to squamous intraepithelial lesions and 3 to
invasive squamous carcinomas and benign lesions such as
irritated endocervical and endometrial polyps or glandu-
lar hyperplasia. 3 cases were Arias-Stella reaction changes.
Due to the lack of sufficiently precise cytological criteria of
atypical glandular cells, considerable inter-observer varia-
bility is associated with the recognition of AGC. This may
also explain the persistent percentage of dysplastic lesions
Table 5: Histological follow-up findings of patients with atypical glandular cells of undetermined significance-not otherwise specified 
(AGUS-NOS) compared to the results of other studies with AGUS including subqualifications (reactive/neoplastic/NOS) [18].
FOLLOWING-UP FINDINGS
STUDY NUMBER OF 
AGUS-cases
BENIGN (%) ADENOCARCINOMA (%) SIL*** (%)
BASE et al19 (1994) 44 9 (20) 0 (0) 35 (80)
BURJA et al20 (1999) 64 26 (41) 3 (5) 35 (54)
DUSKA et al21 (1998) 73 48 (66) 19 (26) 6 (8)
KENNEDY et al22 (1996) 77 60 (78) 10 (13) 7 (9)
JONES and NOVIS8 (1996) 293* 141 (48) 13 (4.5) 116 (40)
RAAB et al23 (1997) 116 50 (43) 16 (14) 50 (43)
SOOFER and SIDAWY18 (2000) 69 52 (75) 7 (10) 10 (15)
OUR SERIES 183** 80 (44) 66 (36) 28 (15)
* The remaining 7.5% of patients had combinations or other significant lesions. ** The remaining 5.0% of patients had other significant lesions i.e. 3 
endometrial adenomatous hyperplasias; 3 metastatic vaginal (2) and ovarian (1) adenocarcinomas; 3 invasive endocervical squamous carcinomas. *** 
SIL: squamous intraepithelial lesions.BMC Cancer 2004, 4:37 http://www.biomedcentral.com/1471-2407/4/37
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of squamous cell origin in our series as well as in other
studies (Table 5). The 'former' AGUS is associated with a
clinically significant lesion of various proportions, rang-
ing from 17% to up to 80% of patients [8,18,20-
22,27,28]. We found clinically significant lesions in 56%
of our AGC-NOS cases (Table 4) suggesting that all
patients with an AGC-NOS diagnosis require further
investigation.
The age distribution of the patients represented in Fig. 1
confirmed that the AGC-NOS diagnoses concerned more
frequently women of age 36 and above, indicating that
this cytologic diagnosis should be made carefully in
patients under 30 years of age to avoid over-diagnosis and
over-treatment.
Referring to the IAC Task Force Summary of 1998, there
was no clear consensus regarding patient management
until 2001 [26]. In analogy to the guidelines for managing
women with AGC issued in 2001 by the American Society
for Colposcopy and Cervical Pathology (ASCCP), we rec-
ommend today a complete and careful evaluation [39-
41]. According to Soofer et al. [18] and Hare et al. [29] and
in order to avoid an inappropriate patient management
due to a misleading qualification (endocervical versus
endometrial origin; squamous or glandular cell type; cell
atypias favouring a reactive or neoplastic etiology) we
support a step-by-step approach of each AGC-NOS diag-
nosis, including colposcopic examination, followed by a
curettage of the cervix and of the corpus to obtain an une-
quivocal histological diagnosis.
Exfoliative cytology has been proven to be an efficacious
technique for the detection of precancerous and cancer-
ous squamous lesions of the cervix. This is not true for
endocervical and especially endometrial lesions of glan-
dular origin [7,41]. As a more detailed sub-classification
of the AGC category may be an additional factor in cyto-
logic-histological discrepancies we prefer not to qualify
AGC diagnoses. Although the AGC-rate reported here is
one of the lowest described, our series presents the high-
est, mostly early stage, malignant rates with predomi-
nantly endometrial lesions, despite the use of cotton
swabs. In contrast with some other studies, however, most
of the lesions were in fact glandular, not squamous. [18-
23]
Conclusion
As 56% of the patients in our series had significant cancer-
ous and precancerous conditions found, patients with not
qualified AGC-diagnosis require complete and careful
evaluation.
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